HYNES CONVENTION CENTER

Boston, Massachusetts
March 8–11, 2020

 

Conference Dates and Location: 
March 4–7, 2019 | Seattle, Washington
Abstract Number: 
608

IMPACT OF HIV ON THE SURVIVAL OF HEPATOCELLULAR CARCINOMA IN HCV-INFECTED PATIENTS

Author(s): 

Nicolás Merchante1, Miguel Rodríguez Fernández1, Blanca Figueruela López1, Francisco Rodríguez-Arrondo2, Boris Revollo3, Sofía Ibarra4, Esperanza Merino5, Maria J. Galindo6, Marta Montero7, Francisco Téllez8, Antonio Rivero-Juárez9, Miguel García-Deltoro10, Ignacio Santos11, Juan A. Pineda1

1Hospital Universitario de Valme, Seville, Spain,2Hospital Donostia, San Sebastián, Spain,3Hospital Germans Trias i Pujol, Barcelona, Spain,4Hospital de Basurto, Basurto, Spain,5Hospital General Universitario de Alicante, Alicante, Spain,6Hospital Clinic of Valencia, Valencia, Spain,7Hospital Universitario y Politecnico La Fe, Valencia, Spain,8Hospital de Puerto Real, Puerto Real, Spain,9Hospital Universitario Reina Sofia, Cordoba, Spain,10Hospital General de Valencia, Valencia, Spain,11Hospital Universitario de La Princesa, Madrid, Spain

Abstract Body: 

Previous studies have suggested that hepatocellular carcinoma (HCC) has a more aggressive presentation and a lower survival in HIV-infected patients. However, the differences in survival found in older studies may be due to a later diagnosis or to lower rates of treatment against HCC, and not to a specific negative impact of HIV infection. Objective: To assess the impact of HIV infection on the survival of HCC in HCV-infected patients.

Methods: Multicenter cohort study (1999-2017). The GEHEP-002 cohort recruits all the HCC cases diagnosed in HIV-infected patients from 32 centers in Spain. For this study, 339 cases diagnosed in HIV/HCV-infected patients were selected. A control population of 118 HCC cases diagnosed in HCV-monoinfected patients during the study period at the Liver Unit from the Hospital de Valme was used. The survival after HCC diagnosis and its predictors, including HIV infection, were assessed.

HCC was diagnosed by surveillance, considered when all scheduled ultrasound had been performed at least within 1 year prior to HCC diagnosis, in 192 (57%) and 73 (62%) HIV+ and HIV- patients, respectively (p=0.3). In spite of similar rates of HCC diagnosis by screening, cases diagnosed in HIV/HCV-coinfected patients were diagnosed at advanced stages. Barcelona-Clinic Liver-Cancer (BCLC) stage at diagnosis was: 0-A 133 (39.6%), B 28 (8.3%), C 118 (35.1%) and D 57 (17%) in HIV+ and 0-A 63 (53.4%), B 21 (17.8%), C 27 (22.9%) and D 7 (5.9%) in HIV- patients (p<0.001). 103 (77%) HIV/HCV-coinfected patients and 4 (70%) HCV-monoinfected patients diagnosed at BCLC stage 0-A underwent curative therapies (p=0.09). 334 (73.1%) patients died, 303 (91%) of them due to HCC. The probability of death at 1-year and 2-year was 53% and 65% in HIV+ and 35% and 57% in HIV- patients (p=0.13). In a Cox model adjusted by age, sex, alcohol consumption, HIV infection and previous SVR, the independent predictors of mortality were BCLC stage at presentation, alfa-fetoprotein levels and lack of previous ultrasound surveillance. HIV infection did not show any trend for an independent association (HR 1.07; 95% CI: 0.74-1.54; p=0.7).

HIV coinfection has no impact on the survival after the diagnosis of HCC in HCV-infected patients. Although the mortality of HCC is somewhat higher in HIV/HCV-coinfected patients, these differences seem to be related with a later diagnosis of HCC in HIV-infected patients and not with HIV infection itself or a lower access to HCC therapy.

Session Number: 
P-K4
Session Title: 
HCV AND HIV: CANCER INFLAMMATION AND FIBROSIS
Presenting Author: 
Nicolás Merchante
Presenter Institution: 
Hospital Universitario de Valme